State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People's Republic of China.
Chem Commun (Camb). 2021 Jun 24;57(51):6308-6311. doi: 10.1039/d1cc02272e.
Here, we describe the identification of PARP1/2 as direct binding proteins of andrographolide (Andro) using protein microarray, surface plasmon resonance (SPR), and enzyme activity assays. We then evaluated the proliferation inhibition, apoptosis, and cell migration effects of Andro on the MDA-MB-436 cell line in vitro. The final biological evaluation confirmed that Andro was a highly effective single agent in the MDA-MB-436 xenograft model and had a low hERG-mediated cardiac toxicity. Therefore, Andro represents the first natural product, non-amide member of a novel nanomolar-potency PARP1/2 inhibitor family.
在这里,我们使用蛋白质微阵列、表面等离子体共振(SPR)和酶活性测定法,描述了 PARP1/2 是穿心莲内酯(Andro)的直接结合蛋白。然后,我们评估了 Andro 对体外 MDA-MB-436 细胞系的增殖抑制、凋亡和细胞迁移的影响。最终的生物学评价证实,Andro 是 MDA-MB-436 异种移植模型中高效的单一药物,且具有低 hERG 介导的心脏毒性。因此,穿心莲内酯是第一个新型纳摩尔效价 PARP1/2 抑制剂家族的天然产物非酰胺成员。